SLC10A6 Inhibitors
Chemical inhibitors of SLC10A6 can exert their inhibitory effects through various mechanisms that interfere with essential processes and conditions required for the protein's function. For instance, Cyclosporin A inhibits SLC10A6 by targeting the calcineurin pathway; this action can alter the phosphorylation state of regulatory proteins, potentially leading to decreased SLC10A6 activity. Similarly, Digoxin and Ouabain exert their inhibitory effects on SLC10A6 by competing with binding sites on the sodium/potassium ATPase pump, which is crucial for establishing the sodium gradient that SLC10A6 utilizes for its transport function. Disruption of this gradient consequently leads to a reduction in the transporter's activity. Probenecid disrupts the ionic balance within the cell, affecting the optimal function of transport proteins, including SLC10A6. Verapamil, by blocking calcium channels, alters the intracellular ionic environment, which can subsequently inhibit the activity of SLC10A6. Amiloride's reduction of sodium reabsorption can lead to the inhibition of sodium-dependent transporters such as SLC10A6 by limiting the availability of sodium ions necessary for their function.
Additionally, Phloretin can disrupt the function of SLC10A6 by affecting the integrity of membrane lipid bilayers, potentially leading to altered transporter activity. Quercetin, through its antioxidant action, can alter cell signaling pathways and membrane dynamics, which can decrease the functionality of SLC10A6. Naringenin, by modifying cell signaling pathways, can affect the phosphorylation states of proteins and thus inhibit the activity of SLC10A6. Genistein's role as a tyrosine kinase inhibitor can also lead to changes in the phosphorylation state of regulatory proteins, resulting in the decreased activity of SLC10A6. Troglitazone can inhibit SLC10A6 via the activation of PPARγ, which can change gene expression profiles and influence the activity of transport proteins. Lastly, Glibenclamide inhibits ATP-sensitive potassium channels, leading to alterations in cellular polarization that can indirectly affect sodium-dependent transporters such as SLC10A6, demonstrating a diverse range of mechanisms through which chemical inhibitors can regulate the activity of this specific transporter protein.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Cyclosporin A can inhibit the protein SLC10A6 by interfering with the calcineurin pathway. SLC10A6 is involved in transporting steroid sulfates and Cyclosporin A's known mechanism of calcineurin inhibition can reduce the cellular activity of transport proteins indirectly by altering the phosphorylation state of various factors involved in transport regulation. | ||||||
12β-Hydroxydigitoxin | 20830-75-5 | sc-213604 sc-213604A | 1 g 5 g | $140.00 $680.00 | ||
12β-Hydroxydigitoxin can inhibit SLC10A6 by competing for binding sites on sodium/potassium ATPase pumps. This competition can indirectly affect SLC10A6 activity since the sodium gradient established by the Na+/K+ pump is crucial for the function of many sodium-dependent transporters, including SLC10A6. By inhibiting the pump, the sodium gradient may be altered, possibly leading to a decrease in SLC10A6 function. | ||||||
Ouabain-d3 (Major) | sc-478417 | 1 mg | $506.00 | |||
Ouabain inhibits SLC10A6 by binding to the sodium/potassium ATPase pump, which is essential for maintaining the sodium gradient that SLC10A6 relies on for its transport function. By inhibiting this pump, ouabain disrupts the gradient and indirectly inhibits the activity of SLC10A6. | ||||||
Probenecid | 57-66-9 | sc-202773 sc-202773A sc-202773B sc-202773C | 1 g 5 g 25 g 100 g | $27.00 $38.00 $98.00 $272.00 | 28 | |
Probenecid acts as an inhibitor of various anion transporters and can inhibit SLC10A6 by disrupting the ionic balance within the cell, which is necessary for the optimal function of transporter proteins. This disruption can lead to a decrease in SLC10A6-mediated transport activity. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
Verapamil is a calcium channel blocker that can inhibit SLC10A6 indirectly by altering the cellular ionic environment, particularly calcium levels. Changes in intracellular calcium can affect the activity of various transport proteins, including SLC10A6. | ||||||
Amiloride | 2609-46-3 | sc-337527 | 1 g | $290.00 | 7 | |
Amiloride can inhibit SLC10A6 by reducing sodium reabsorption, which is critical for sodium-dependent transporters. As SLC10A6 is a sodium-dependent transporter, the reduction in available sodium ions can indirectly inhibit its activity. | ||||||
Phloretin | 60-82-2 | sc-3548 sc-3548A | 200 mg 1 g | $63.00 $250.00 | 13 | |
Phloretin can inhibit SLC10A6 by disrupting membrane lipid bilayers and affecting membrane-associated transport processes. This disruption can alter the function of various transport proteins, including SLC10A6. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $108.00 $245.00 $918.00 $49.00 | 33 | |
Quercetin can inhibit SLC10A6 through its general actions as an antioxidant, which can alter cell signaling pathways and membrane dynamics, potentially leading to decreased function of transporter proteins. | ||||||
Naringenin | 480-41-1 | sc-219338 | 25 g | $245.00 | 11 | |
Naringenin can inhibit SLC10A6 by altering cell signaling pathways and affecting the phosphorylation states of proteins, which can indirectly decrease the activity of transport proteins such as SLC10A6. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein can inhibit SLC10A6 by acting as a tyrosine kinase inhibitor, which may lead to an altered phosphorylation state of proteins involved in the regulation of transporter activity, including SLC10A6. | ||||||